Exploration of costunolide derivatives as potential anti-inflammatory agents for topical treatment of atopic dermatitis by inhibiting MAPK/NF-κB pathways.

Atopic dermatitis Costunolide MAPK/NF-κB Th2-type cytokines

Journal

Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703

Informations de publication

Date de publication:
25 Dec 2023
Historique:
received: 18 10 2023
revised: 12 12 2023
accepted: 21 12 2023
medline: 2 1 2024
pubmed: 2 1 2024
entrez: 29 12 2023
Statut: aheadofprint

Résumé

Atopic dermatitis (AD) is a common inflammatory disease and it is very difficult to treat. In the present work, a series of costunolide derivatives have been prepared, and in vitro and in vivo anti-inflammatory activities have evaluated. The results showed that most derivatives displayed good inhibition of NO generation with low cytotoxicity, and 7d could inhibit the phosphorylation of P38, P65 NF-κB and IκB-α in LPS-induced RAW264.7 model. The in vivo researches showed that 7d could improve skin injury symptoms, decrease Th2-type cytokine levels, inhibit HIS levels, alleviate scratching and repaire the damaged skin barrier through the inhibition of phosphorylation of MAPK and NF-κB signaling pathways on MC903-induced AD model. Therefore, costunolide derivatives may be new potent anti-AD agents for further study.

Identifiants

pubmed: 38157670
pii: S0045-2068(23)00715-0
doi: 10.1016/j.bioorg.2023.107054
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107054

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Cheng Lu (C)

School of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming 650500, PR China.

Xiaoyi Li (X)

School of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming 650500, PR China.

Wenxia Du (W)

School of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming 650500, PR China.

Xiao Zhang (X)

School of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming 650500, PR China.

Yanping Li (Y)

School of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming 650500, PR China.

Chunyan Hu (C)

School of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming 650500, PR China.

Zewei Mao (Z)

School of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming 650500, PR China. Electronic address: maozw@ynutcm.edu.cn.

Yi Zhang (Y)

School of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming 650500, PR China. Electronic address: zhangyi@ynutcm.edu.cn.

Ruirui Wang (R)

School of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming 650500, PR China. Electronic address: wangrryucm@126.com.

Classifications MeSH